Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pricing Debate

Set Alert for Pricing Debate

Expect Industry To Step Up Drug Pricing Self-Regulation In 2017 – PwC

As industry begins to organize around broader self-regulation on drug pricing, PwC Partner Rick Judy expects pharma companies to announce more social contracts with consumers. Industry self-regulation on prices is one of 10 top health issues for 2017 identified by the consulting firm.

Policy & Regulation Pricing Strategies Commercial

Latest From Pricing Debate

Rx Spending Stands Out In CMS Projections – As Slowing Down

Pharmaceutical industry’s message on overall drug spending trends is getting some timely support from the Center for Medicare and Medicaid Services’ annual national health expenditure projections.

Pricing Debate Policy

Generic Industry Hit With Avalanche Of Price Fixing Suits

As state attorneys general and Department of Justice move against generic manufacturers, plaintiffs’ firms have filed more than 90 antitrust suits on behalf of third party payers.

BioPharmaceutical Policy

Cost Versus Value: Earnings Calls Spotlight US Pricing Reforms

Pink Sheet has scoured big pharma annual results presentations to gauge the industry's reactions and concerns around the increasingly tough US drug pricing environment and proposed changes to the Affordable Care Act under the new Trump administration.

Pricing Debate Pricing Strategies

Medicaid Drug Rebates Will Get Closer Scrutiny From CMS, Verma Pledges

CMS Administrator-nominee Seema Verma promises stronger agency oversight of Medicaid drug rebate program in response to question from Sen. Grassley during Senate confirmation hearing.

Policy Medicaid

Turkey Grapples With Spinraza Cost As Patients Seek Access

Families of spinal muscular atrophy patients in Turkey are demanding immediate access to Biogen’s Spinraza following its US approval in December. Its public payer is in discussions over possible reimbursement of the high-priced imported drug but the company is said to have shown no pricing flexibility so far.

Turkey Pricing Debate

Part Of The Solution? PBMs See Opportunities In Medicaid Reform

Amidst a growing chorus of criticism that pharmacy benefit managers are contributing to the problem of high drug costs, PCMA’s Merritt defends the PBM business model and points to its potential for better managing costs in Medicaid.

Pharmacy Benefit Management Pricing Debate

Sweeping FDA Changes Could Have “Disastrous Consequences” For Biotech Investment

Lowering the bar on drug approval standards would create a challenging environment for biotech investors, warned Jonathan Leff, a partner at the health care investment firm Deerfield, during the BIO CEO & Investor Conference.

Pricing Debate Medicare

Time For Big Pharma To Take Back Orphan Drugs

The controversy over Marathon’s pricing of the steroid deflazacort is fueling calls to revisit the US Orphan Drug Act. For Big Pharma companies, the threat should not be ignored. It is time for the industry’s biggest players to take back development of products like deflazacort to protect pricing for more innovative therapies.

Pricing Debate Policy

Value-Based Contracts: Relief From Regulatory Barriers In Sight?

Novartis CEO Jimenez suggests Trump Administration may help remove regulatory barriers to US outcome-based contracting between manufacturers and payers; Duke Margolis Center for Health Policy plans policy initiative to promote value-based purchasing for drugs, medical devices and gene therapy.

Pricing Debate US Election 2016
See All
UsernamePublicRestriction

Register